Brokerages Expect Deciphera Pharmaceuticals Inc (DCPH) Will Announce Earnings of -$0.76 Per Share
Brokerages expect Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) to post earnings per share of ($0.76) for the current quarter, according to Zacks. Zero analysts have provided estimates for Deciphera Pharmaceuticals’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.96). Deciphera Pharmaceuticals reported earnings per share of ($0.66) during the same quarter last year, which suggests a negative year over year growth rate of 15.2%. The firm is expected to announce its next quarterly earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Deciphera Pharmaceuticals will report full year earnings of ($2.93) per share for the current fiscal year, with EPS estimates ranging from ($3.92) to ($1.51). For the next year, analysts expect that the firm will report earnings of ($3.52) per share, with EPS estimates ranging from ($4.46) to ($3.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Thursday, March 14th. The company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.13).
Shares of DCPH stock traded down $0.50 on Thursday, hitting $23.14. 6,719 shares of the company’s stock traded hands, compared to its average volume of 186,504. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.24 and a current ratio of 13.24. Deciphera Pharmaceuticals has a one year low of $18.55 and a one year high of $45.61. The firm has a market cap of $897.47 million, a P/E ratio of -8.27 and a beta of 3.18.
In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 1,700 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $28.01, for a total transaction of $47,617.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Daniel Lee Flynn sold 152,629 shares of the business’s stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $26.00, for a total transaction of $3,968,354.00. The disclosure for this sale can be found here. Insiders have sold 193,426 shares of company stock worth $5,121,946 in the last quarter. Company insiders own 20.61% of the company’s stock.
A number of hedge funds have recently bought and sold shares of DCPH. Legal & General Group Plc grew its holdings in shares of Deciphera Pharmaceuticals by 55.4% in the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after purchasing an additional 587 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Deciphera Pharmaceuticals by 14.1% in the third quarter. Teachers Advisors LLC now owns 17,187 shares of the company’s stock worth $665,000 after purchasing an additional 2,119 shares during the last quarter. Great West Life Assurance Co. Can bought a new position in shares of Deciphera Pharmaceuticals in the fourth quarter worth about $50,000. Rhumbline Advisers grew its holdings in shares of Deciphera Pharmaceuticals by 53.6% in the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Highland Capital Management LP grew its holdings in shares of Deciphera Pharmaceuticals by 50.0% in the third quarter. Highland Capital Management LP now owns 15,000 shares of the company’s stock worth $581,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 57.37% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.